External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort

Mottet, 2020, EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer 2020 Louie, 2015, Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis, Ann Oncol, 26, 848, 10.1093/annonc/mdu525 Ankerst, 2018, A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts, Eur Urol, 74, 197, 10.1016/j.eururo.2018.05.003 Roobol, 2010, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025 De Nunzio, 2018, External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: a single center cohort-study, Urol Oncol, 36, 364.e1, 10.1016/j.urolonc.2018.05.010 Poyet, 2016, BJU Int, 117, 401, 10.1111/bju.13314 Gayet, 2018, Prediction of prostate cancer: external validation of the ERSPC Risk Calculator in a contemporary Dutch clinical cohort, Eur Urol Focus, 4, 228, 10.1016/j.euf.2016.07.007 Gomez-Gomez, 2017, European randomized study of screening for prostate cancer risk calculator: external validation, variability, and clinical significance, Urology, 102, 85, 10.1016/j.urology.2016.11.004 Mortezavi, 2021, Head-to-head comparison of conventional, and image- and biomarker-based prostate cancer risk calculators, Eur Urol Focus, 7, 546, 10.1016/j.euf.2020.05.002 Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Eklund, 2021, MRI-targeted or standard biopsy in prostate cancer screening, N Engl J Med, 385, 908, 10.1056/NEJMoa2100852 Vickers AJ, Russo G, Lilja H, et al. How should molecular markers and magnetic resonance imaging be used in the early detection of prostate cancer? Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.01.010. Gronberg, 2015, Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study, Lancet Oncol, 16, 1667, 10.1016/S1470-2045(15)00361-7 SWOP – The Prostate Cancer Research Foundation Reeuwijk. The Prostate Cancer Risk Calculator 3 and 4 with TRUS or DRE. http://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators. Prostate Biopsy Collaborative Group. PBCG risk calculator. http://riskcalc.org/PBCG. Steyerberg, 2009 Van Calster, 2018, Reporting and interpreting decision curve analysis: a guide for investigators, Eur Urol, 74, 796, 10.1016/j.eururo.2018.08.038 Strobl, 2015, Improving patient prostate cancer risk assessment: moving from static, globally-applied to dynamic, practice-specific risk calculators, J Biomed Inform, 56, 87, 10.1016/j.jbi.2015.05.001 Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making, 26, 565, 10.1177/0272989X06295361 van Vugt, 2011, Prediction of prostate cancer in unscreened men: external validation of a risk calculator, Eur J Cancer, 47, 903, 10.1016/j.ejca.2010.11.012 Nordstrom, 2018, Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer, Prostate Cancer Prostatic Dis, 21, 57, 10.1038/s41391-017-0024-7 Roobol, 2013, Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer, Eur Urol, 64, 530, 10.1016/j.eururo.2013.05.030 Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma, Am J Surg Pathol, 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Osses, 2019, Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis, Int J Mol Sci, 20, 1637, 10.3390/ijms20071637 Braun, 2016, A four-kallikrein panel predicts high-grade cancer on biopsy: independent validation in a community cohort, Eur Urol, 69, 505, 10.1016/j.eururo.2015.04.028 Nordstrom, 2014, A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1–3 ng/ml, Eur Urol, 65, 1184, 10.1016/j.eururo.2013.07.005 Statistics Sweden. The Statistics Database. Population by country of birth, age and sex. Year 2000–2021. Statistics Sweden Web site. http://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__BE__BE0101__BE0101E/FodelselandArK/.